Research Article

Seroprevalence Investigation of Hepatitis B and Hepatitis B Core Antigen in Oncology Patients


  • İrem Akdemir Kalkan
  • Ayşe Demirci
  • Güle Çınar
  • Mustaka Kemal Çelen

Received Date: 26.09.2019 Accepted Date: 30.09.2020 Viral Hepat J 0;0(0):0-0 [e-Pub]


Hepatitis B virus affects a significant part of society and is characterized by high mortality and morbidity. Hepatitis B affects approximately 350 million people worldwide, many of whom are chronic patients. Especially being under immunosuppressive therapy is a risk factor for the reactivation of the disease. The aim of this study was to investigate the seroprevalence of hepatitis B in oncology patients.

Materials and Methods:

In this study, the seroprevalences of HBsAg, anti-HCV, anti-HBs, and anti-HBc IgG were retrospectively evaluated from the medical records of 84 patients who were diagnosed of cancer, and were admitted to the outpatient clinic of medical oncology in the state hospital within a period of one year (Between January and December 2017).


Anti-Hbc IgG was positive in 44 patients (52.2%),16 (36.4%) have received treatment for the prevention of HBV reactivation Six of these patients were HBsAg positive No reactivation and no side effects occur in patients who received prophylactic antiretroviral treatment.


In our study, both the proportion of patients with HBsAg positivity and the proportion of patients with natural immunity were found to be slightly higher than those in Turkey and worldwide. No patients with hepatitis B reactivation is important evidence of necessity effectiveness of prophylactic antiviral treatment

Keywords: Hepatitis B, oncology, Hepatitis B virus reactivation